Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 5, 2002, Pages 2107-2113

  Cristina Meriggiola, M ^{a,b,c,d,e,f,g}   Bremner, William J ^a,b,c,d,e,f   Costantino, Antonietta ^a,b,c,d,e,f   Bertaccini, Alessandro ^a,b,c,d,e,f   Morselli Labate, Antonio Maria ^a,b,c,d,e,f   Huebler, Doris ^a,b,c,d,e,f   Kaufmann, Guenter ^a,b,c,d,e,f   Oettel, Michael ^a,b,c,d,e,f   Flamigni, Carlo ^a,b,c,d,e,f  

^a Clinic of Obstetrics and Gynecology   (United States)

^b Department of Internal Medicine and Gastroenterology   (United States)

^c Malpighi Hospital   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF WASHINGTON   (United States)

^f BAYER PHARMA AG   (Germany)

^g UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; CYPROTERONE ACETATE; DIENOGEST; FOLLITROPIN; GONADOTROPIN; LUTEINIZING HORMONE; MALE CONTRACEPTIVE AGENT; PLACEBO; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLITROPIN BLOOD LEVEL; HORMONAL CONTRACEPTION; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEMEN ANALYSIS; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL;

ADULT; CONTRACEPTIVE AGENTS, MALE; DRUG ADMINISTRATION SCHEDULE; GONADOTROPINS; HORMONES; HUMANS; MALE; NANDROLONE; PENILE ERECTION; REFERENCE VALUES; SPERMATOGENESIS; TESTOSTERONE;

EID: 0036090403     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.87.5.2107     Document Type: Article

References (37)

1. Contraceptive efficacy of testosterone-induced azoospermia in normal men
2. Rates of testosterone-induced suppression to severe oligozoospermia or azoospermia in two multinational clinical studies
3. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men
4. Progestin-androgen combination regimens for male contraception
5. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects higher dosage combinations
6. Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and HDL suppression
7. A promising male contraceptive approach: Combined administration of testosterone and levonorgestrel
8. Oral progestogen combined with testosterone as a potential male contraceptive additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism
9. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot
10. Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by addition of finasteride
11. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception
12. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive
13. Low dose of cyproterone acetate and testosterone enanthate for contraception in men
14. Hybrid progestins: The example of dienogest
15. Non-protein bound dienogest in serum and salivary dienogest in women taking the oral contraceptives Certostat® and Valette®
16. Bovine serum albumin conjugates of the new progestagen dienogest. Synthesis and immunogenic properties
17. Metabolic and behavioural effects of high-dose, exogenous testosterone in healthy men
18. Parameters of prostate volume and shape in community based population of men 55 to 74 years old
19. Dienogest
20. A 19-norprogestin without 17-α ethinil group. II. Dienogest from a pharmacokinetic point of view
21. A 19-norprogestin without 17-α ethinyl group. II. Dienogest from a pharmacodynamic point of view
22. Pharmacokinetics of dienogest as single agent and in combination with ethinylestradiol
23. Indices of gonadal function in the human male. II. Seminal plasma levels of steroids in normal and pathological conditions
24. Endocrine, seminal and peripheral effects of depot medroxyprogesterone acetate and testosterone enanthate in men
25. Steroid conjugates in human seminal plasma
26. Effect of STS-557 (17α-cyanomethyl 17β-hydroxy-estra-4,9(10)-dien-3-one) on blood hormone levels, the testis, accessory sex organs and fertility of rats
27. Effect of STS 557 on semen composition, fertility and sexual behavior of male rabbit
28. Effects of levonorgestrel and STS 557 on testis in rodents
29. Inhibition of male fertility by STS 557
30. Evaluation of STS 557 as an oral contraceptive in male rat
31. Fertilizing ability of spermatozoa of rats treated with STS 557
32. Contraceptive potentiality of STS-557-a feasibility study in male Bonnet monkey (Macaca radiata)
33. Effects of STS-557 and 20 Aet-1 on sperm function and serum level of testosterone in bonnet monkey (Macaca radiata)